Business
Premier Biomedical, Inc. Engages Agent to Identify Suitable Joint Venture Partners in China and Europe
Premier Biomedical, Inc. Engages Agent to Identify Suitable Joint Venture Partners in China and Europe.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc. (OTCQB: \n BIEI) announced that they have engaged the services of an agent \n affiliated with the Chinese pharmaceutical industry to seek out suitable \n joint venture partners in China and Europe. The agent will act in \n Premier’s interests in locating and securing financing and suitable \n joint venture partners in China and Europe for the purposes of testing, \n registering and marketing medications and devices being developed by \n Premier for the treatment of various diseases, such as fibromyalgia, MS, \n and cancer.\n \n \n William A. Hartman, President and CEO of Premier Biomedical, stated, “We \n believe there are significant advantages in seeking a joint venture with \n Chinese and European biomedical/pharmaceutical partners, and see this as \n the next step to expanding our potential market coverage. This effort \n does not lessen the importance of securing similar JV arrangements in \n Brazil, India, and the rest of Asia, but, in fact, complements those \n efforts.”\n \n \n About Premier Biomedical, Inc.\n \n \n Premier \n Biomedical, Inc. (OTCQB: \n BIEI) is a biotech research public company focused on discovering, \n developing, and commercializing medical treatments for a wide range of \n diseases in humans. Premier has obtained, via exclusive license \n agreements, the technology behind three granted US Patents, multiple \n pending provisional patents, and a PCT Europe National Patent. Founded \n in 2010, Premier has partnered with the Department of Defense with \n Center of Expertise at the William Beaumont Army Medical Center and the \n University of Texas El Paso (UTEP). The company’s R&D efforts are \n centered in El Paso, TX, and their business offices are in Western \n Pennsylvania. The Company is a fully-reporting issuer whose common stock \n trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. \n under the ticker symbol “BIEI.” http://www.premierbiomedical.com/\n \n \n Safe Harbor Notice\n \n \n Statements made in this news release constitute forward-looking \n statements as defined in the Private Securities Litigation Reform Act of \n 1995. Premier Biomedical makes no guarantee of future performance and \n actual results could differ materially. Premier Biomedical, Inc. \n undertakes no obligation to revise or update ...